Cancer Immunotherapy

Antigen-Targeted Therapy Uses scFv Fusion Proteins

Published in Monoclonal Antibodies Weekly, January 26th, 2000

Tumor cell targeting of immune effector molecules can be accomplished with tumor associated antigen specific single chain antibody (scFv) fusion proteins, reported researchers from England.

"Expression of the cell-surface oncofetal antigen, 5T4, is strongly associated with a wide spectrum of human cancers and is an excellent putative target for tumor-antigen targeted immunotherapy," wrote K. A. Myers and colleagues from Oxford BioMedica Ltd., and Paterson Institute for Cancer Research, England. "We have constructed a scFv derived from a monoclonal antibody specific for 5T4."

Data from their study was presented at the 7th Meeting of the European...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly

Source: Monoclonal Antibodies Weekly (2000-01-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry